Showing 4171-4180 of 10733 results for "".
- Judge Blocks Launch of Xeomin for Aesthetic Indicationshttps://practicaldermatology.com/news/20120307-judge_blocks_launch_of_xeomin_for_aesthetic_indications/2459852/The planned March 12 launch of Merz's Xeomin (incobotulinumtoxinA) for aesthetic indications will almost certainly be delayed due to a court order blocking marketing of incobotulinumtoxinA. The order comes in response to a suit by
- FDA Approves Methoxsalen USP Providerhttps://practicaldermatology.com/news/20120229-fda_approves_methoxsalen_usp_provider/2459859/FDA has approved a secondary supplier of Methoxsalen USP, prescribed under the brand name Oxsoralen-Ultra® (methoxsalen) Capsules, USP, 10mg. Valeant Dermatology, a division of Valeant Pharmaceuticals North America LLC, and marketer of the
- Review Integrates Functional and Aesthetic BTX-A Treatment for Facial Paralysishttps://practicaldermatology.com/news/review-integrates-functional-and-aesthetic-btx-a-treatment-for-facial-paralysis/2488325/Botulinum toxin A (BTX-A) may offer dermatologists a way to address the functional, therapeutic, and aesthetic manifestations of facial paralysis within a single treatment framework, a recent review suggested.d BTX-A Targets Multiple Sequelae of Facial Paralysis The authors conduc
- Outpatient Dermatology Care Linked to Fewer HS Hospital Readmissions: Analysishttps://practicaldermatology.com/news/outpatient-dermatology-care-linked-to-fewer-hs-hospital-readmissions-analysis/2488266/Hidradenitis suppurativa (HS) carries a significant acute-care burden, but outpatient dermatology follow-up may be associated with fewer hospital readmissions, according to a study published in Archives of Dermatological Research
- Brepocitinib Improves Cutaneous Dermatomyositis Outcomes Through 52 Weekshttps://practicaldermatology.com/news/brepocitinib-30-mg-improves-cutaneous-dermatomyositis-outcomes-through-52-weeks/2488228/Once-daily oral brepocitinib 30 mg improved skin disease activity, pruritus, and skin-related quality of life in adults with dermatomyositis as early as 4 weeks, according to results from an analysis of phase data from the 3 VALOR trial. The analysis included data from 241 adults with acti
- Review Explores Energy-based Devices in Gender-affirming Carehttps://practicaldermatology.com/news/review-explores-energy-based-devices-in-gender-affirming-care/2488181/Laser and energy-based devices (EBDs) may address several dermatologic concerns relevant to transgender patients, from unwanted hair and acne to postoperative scars and body contouring, according to a recent review by Zarghami et al. Laser Applications Span Hair Removal, Acne, and Postsur
- Analysis: IBS Associated With 35% Higher Long-Term Risk of Psoriasishttps://practicaldermatology.com/news/analysis-ibs-associated-with-35-higher-long-term-risk-of-psoriasis/2488177/A large prospective cohort study showed a link between irritable bowel syndrome (IBS) and an elevated long-term risk of developing psoriasis compared to those without IBS.
- INTerpath-001: Intismeran Plus Pembrolizumab Meets Dual Phase 3 Melanoma Endpointshttps://practicaldermatology.com/news/intismeran-plus-pembrolizumab-meets-dual-phase-3-melanoma-endpoints/2488176/Merck and Moderna reported positive topline results from the phase 3 INTerpath-001 trial evaluating intismeran autogene (V940; mRNA-4157) plus pembrolizumab (Keytruda) as adjuvant therapy for completely resected stage IIB-IV cutaneous melanoma. The individualized mRNA-based neoantigen ther
- LEO Pharma Acquires Worldwide Rights to Dersimelagon for EPP, XLPhttps://practicaldermatology.com/news/leo-pharma-acquires-worldwide-rights-to-dersimelagon-for-epp-xlp/2488131/LEO Pharma has entered into an agreement to acquire worldwide rights to dersimelagon from Tanabe Pharma, adding a late-stage investigational therapy for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) to its rare dermatology pipeline. Under the agreement, LEO Pharma w
- Occupational Exposures Implicated in More Than Half of Chronic Hand Eczema Caseshttps://practicaldermatology.com/news/occupational-exposures-implicated-in-more-than-half-of-chronic-hand-eczema-cases/2488120/A new retrospective study of adults with chronic hand eczema (CHE) found allergic contact dermatitis (ACD) and occupational exposures were common, while most patients improved following diagnosis and treatment recommendations that included allergen avoidance. Investigators evaluated 76 adu